Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus casei DN-114001, also known by its current nomenclature Lacticaseibacillus paracasei subsp. paracasei and code CNCM I-1518, is a probiotic bacterial strain developed by Danone. [3, 11] It is the active ingredient in the fermented dairy drinks marketed as Actimel in Europe and DanActive in the United States. [3, 4] As a live biologic organism, this probiotic is designed to survive gastrointestinal transit to modify the gut microflora and enhance the host's immune system. Its mechanism of action is multifactorial, involving adhesion to intestinal epithelial cells, inhibition of pathogenic bacteria, strengthening of the gut barrier function, and modulation of the immune system. [21] The strain has been clinically studied for the prevention and treatment of various conditions, including different forms of diarrhea (such as antibiotic-associated diarrhea), atopic dermatitis, common infectious diseases, inflammatory bowel diseases, and respiratory infections. [3, 7, 16, 17]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus casei DN-114001.